Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1573022 | 0.92 | ADORA1 (0.39) | KDM4EPKMENPP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1572984 | 0.91 | L3MBTL1 (0.45) | KDM4EENPP1LMNAALDH1A1HPGD | |
| SCHEMBL3397783 | 0.86 | PTGS2 (0.40) | LMNAALDH1A1SMN1; SMN2PTGS1PDE4A | |
| SCHEMBL1573094 | 0.86 | PTGS2 (0.57) | PTGS1PTGS2 | |
| SCHEMBL6530623 | 0.85 | KDM4E (0.39) | KDM4EPKMENPP1LMNAALDH1A1 | |
| SCHEMBL2082760 | 0.85 | PDE4A (0.49) | LMNAPTGS1PDE4APDE4BPDE4C | |
| SCHEMBL27750165 | 0.84 | PTGS2 (0.55) | PTGS1PTGS2 | |
| SCHEMBL27729749 | 0.84 | PSD (0.35) | KDM4EPKMENPP1LMNAALDH1A1 | |
| SCHEMBL14288875 | 0.82 | PTGS2 (0.33) | KDM4EPKMENPP1LMNAALDH1A1 | |
| SCHEMBL14313994 | 0.82 | RARA (0.34) | LMNAALDH1A1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542978-B1 | NOVEL BIO-ACTIVE MOLECULES | ORCHID RES LAB LTD (IN) | 2011-04-13 | — | — | EP | claimed |
| US-7317014-B2 | Bio-active pyrimidine molecules | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2008-01-08 | — | — | US | claimed |
| US-20050107413-A1 | Novel bio-active molecules | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2005-05-19 | — | — | US | claimed |
| EP-1973884-B1 | NOVEL HETEROCYCLES | ORCHID PHARMA LTD (IN) | 2016-08-03 | — | — | EP | disclosed |
| US-8828999-B2 | Pyrimidine compounds and their uses | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2014-09-09 | — | — | US | disclosed |
| US-20130172350-A1 | PYRIMIDINE COMPOUNDS AND THEIR USES | ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2013-07-04 | — | — | US | disclosed |
| US-8420653-B2 | Pyrimidine compounds and their uses | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-04-16 | — | — | US | disclosed |
| EP-1542978-B1 | NOVEL BIO-ACTIVE MOLECULES | ORCHID RES LAB LTD (IN) | 2011-04-13 | — | — | EP | disclosed |
| EP-1542978-B1 | NOVEL BIO-ACTIVE MOLECULES | ORCHID RES LAB LTD (IN) | 2011-04-13 | — | — | EP | disclosed |
| US-7863446-B2 | Heterocycles | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2011-01-04 | — | — | US | disclosed |
| US-20100329998-A1 | NOVEL HETEROCYCLES | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2010-12-30 | — | — | US | disclosed |
| US-20080207606-A1 | Novel heterocycles | ORCHID RESEARCH LABORATORIES LIMITED. (IN) | 2008-08-28 | — | — | US | disclosed |
| US-7317014-B2 | Bio-active pyrimidine molecules | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2008-01-08 | — | — | US | disclosed |
| US-7317014-B2 | Bio-active pyrimidine molecules | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2008-01-08 | — | — | US | disclosed |
| US-7317014-B2 | Bio-active pyrimidine molecules | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2008-01-08 | — | — | US | disclosed |
| WO-2007083182-A2 | NOVEL HETEROCYCLES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-07-26 | — | — | WO | disclosed |
| US-20070167413-A1 | Novel heterocycles | ORCHID RESEARCH LABORATORIES LIMITED. (IN) | 2007-07-19 | — | — | US | disclosed |
| EP-1542978-A1 | NOVEL BIO-ACTIVE MOLECULES | Orchid Chemicals and Pharmaceuticals Ltd (IN) | 2005-06-22 | — | — | EP | disclosed |
| US-20050107413-A1 | Novel bio-active molecules | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2005-05-19 | — | — | US | disclosed |
| WO-2004009560-A1 | NOVEL BIO-ACTIVE MOLECULES | ORCHID CHEMICALS & PHARMACEUTICALS LTD (IN) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207606-A1 | Novel heterocycles | GPR4, UACA, PDE4A | KDM4E 2926/4885PKM 1336/4885ENPP1 1468/4885 |
| US-20100329998-A1 | NOVEL HETEROCYCLES | UACA, GPR4, CASP4 | KDM4E 2809/4885PKM 1150/4885ENPP1 1297/4885 |
| US-20050107413-A1 | Novel bio-active molecules | ABCG2, UGT2B7, UGT1A1 | KDM4E 4794/4885PKM 1297/4885ENPP1 159/4885 |
| US-20070167413-A1 | Novel heterocycles | MCL1, UACA, MYLK2 | KDM4E 4714/4885PKM 1793/4885ENPP1 2756/4885 |
| US-20130172350-A1 | PYRIMIDINE COMPOUNDS AND THEIR USES | UMPS, PNP, PDE4A | KDM4E 2898/4885PKM 963/4885ENPP1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.